R&D

SAMOH aims to provide healthier and
happier life of mankind.
Plant & R&D center
Sihwa Plant
SAMOH Pharm. Co., Ltd. constructed a new synthetic plant in the industrial complex of Siheung city in Sep. 1999, in order to supply drug substances of high quality. Thereafter, this plant was subsequently approved by local agency (known as Korea FDA) in 2002.
Furthermore, the plant was remodeled in 2012 in compliance with GMP requirements for overseas markets of Europe and Japan.
On the basis of these advanced GMP facilities, all employees are doing their best in their positions for manufacturing drug substances of best quality.
SAMOH Pharm is committed to excellence in all the GMP processes based on strict quality control and customer's reliance.
2019
  • 2Registered for DMF OF Diclofenac Epolamine to Italy
  • 1Preparing DMF for the purpose of registering Diclofenac Epolamine to
    4 EU countries (France, Belgium, Greece, Portugal) by Italy agency (AIFA)
2018
  • 12Audited by MFDS (Korea agency) for several manufacturing methods
    (Chemical synthesis)
2017
  • 4Registered for DMF of Methylprednisolone Aceponate to Turkey
2016
  • 1Audited by MFDS (Korea agency) for several manufacturing methods
    (Chemical synthesis)
2015
  • 7Registered for Loxoprofen Sodium DMF to PMDA
2013
  • 12Consulted & Audited by SOPHARM (Authorized auditor)
2012
  • 12Consulted & Audited by SOPHARM (Authorized auditor)
  • 5Remodeled building A, B and C, and constructed building D
2006
  • 9Registered Sihwa Plant to PMDA (Rebamipide)
2004
  • 8Applied DMF of Aceclofenac, Tiroprimide HCl, Levosulpiride and Rebamipide to MFDS (Korea agency)
2002
  • 4Approved GMP for Sihwa Plant by MFDS (Korea agency)
2001
  • 7Reconstructed building A & Constructed building C
1999
  • 9Sihwa Plant was started (Address : 63, Okgucheonseo-ro 81beon-gil, Siheung-si, Gyeonggi-do, Korea)